에 대한 최신 뉴스 CareDx (NASDAQ:CDNA) 주식

CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

CareDx Inc

CANADIAN TIRE LTD A by Canadian Tire Corp. Ltd.

Canadian Tire Corp Ltd

CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024.

News

Management

CDNA

CareDx Names Keith Kennedy As COO And Jessica Meng As Chief Commercial Officer

Wells Fargo analyst Brandon Couillard initiates coverage on CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Underweight rating and announces Price Target of $28.

Price Target

Initiation

Analyst Ratings

Wells Fargo Initiates Coverage On CareDx with Underweight Rating, Announces Price Target of $28

In the last three months, 4 analysts have published ratings on CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.5, a high estimate of $40.00, and a low estimate of $16.00. Witnessing a positive shift, the current average has risen by 64.45% from the previous average price target of $17.33.
<img src="https://www.benzinga.com/files/images/story/2024/1724076012_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CareDx. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CareDx's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CareDx's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into CareDx's Background</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>CareDx: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: CareDx displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 31.26%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CareDx's net margin excels beyond industry benchmarks, reaching -1.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): CareDx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.54%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CareDx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: CareDx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About CareDx

BTIG analyst Sung Ji Nam upgrades CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) from Neutral to Buy and announces $40 price target.

Upgrades

BTIG Upgrades CareDx to Buy, Announces $40 Price Target

WIIM

CareDx shares are trading higher after the CMS retired a draft policy that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection.

CareDx Announces CMS Retires Draft Policy Restricting Coverage, Restoring Longstanding Coverage For AlloSure, AlloMap, And HeartCare Through Surveillance Testing For Allograft Rejection

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $16 to $26.

Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $26

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $22 to $32.

Craig-Hallum Maintains Buy on CareDx, Raises Price Target to $32

HC Wainwright &amp; Co. analyst Yi Chen reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on CareDx

Shares of Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/24/07/40082489/carvana-q2-earnings-revenue-beat-eps-beat-vehicle-sales-jump-33-upbeat-guidance-and-more">second-quarter financial results</a>.
Carvana reported second-quarter revenue of $3.41 billion, beating the consensus estimate of $3.244 billion, according to Benzinga Pro. The used car retailer reported quarterly earnings of 14 cents per share, beating analyst estimates for a loss of 12 cents per share.
Carvana shares jumped 13.4% to $151.12 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 55.2% to $0.1568 in pre-market trading after falling 7% on Wednesday.</li>
<li>Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) gained 37.2% to $1.55 in pre-market trading after the company announced that IMM-1-104 was granted Fast Track designation from the FDA.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) rose 23% to $24.58 in today's pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) jumped 22.1% to $17.91 in pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares gained 20.8% to $2.61 in pre-market trading after gaining 23% on Wednesday.</li>
<li>Olo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) shares gained 19.1% to $5.69 in pre-market trading after the company reported better-than-expected second-quarter sales results.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) shares rose 17.5% to $8.31 in pre-market trading following upbeat quarterly results.</li>
<li>Kaixin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares gained 17.5% to $0.1308 in pre-market trading after the company announced it received a non-compliance notification from the Nasdaq.</li>
<li>Rush Street Interactive, Inc. (NYSE RSI) shares rose 16.8% to $11.69 in pre-market trading after the company reported better-than-expected second-quarter earnings and raised FY24 revenue forecast.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) shares dipped 25.8% to $3.56 in pre-market trading. The company announced it will host an investor call and webcast to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.</li>
<li>noco-noco Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares fell 21.9% to $0.2240 in pre-market trading after jumping 88% on Wednesday.</li>
<li>Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares declined 18.9% to $8.19 in pre-market trading after the company reported second-quarter results.</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) fell 16.7% to $7.70 pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares declined 16.3% to $7.89 in pre-market trading following weak quarterly sales results.</li>
<li>Tenable Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) shares fell 14% to $39.51 in pre-market trading after the company reported second-quarter financial results.</li>
<li>Standard Biotools Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) dipped 12.9% to $1.95 in pre-market trading after the company posted weak second-quarter results.</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) shares declined 11.1% to $22.24 in pre-market trading after the company reported second-quarter financial results and issued third-quarter EPS guidance below estimates.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares fell 9.6% to $130.28 in pre-market trading following weak second-quarter guidance.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) fell 6.3% to $ 62.81 in today's pre-market trading after the company reported its fourth-quarter financial results.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/markets/24/07/40067769/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 4% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALXO

ATEC

BBLG

CFLT

CVNA

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

IMRX

KXIN

NCNC

NOVA

TDOC

TENB

UDMY

Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

CareDx shares are trading higher after the company reported better-than-expected Q2 financial results.

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.14) by 278.57 percent. This is a 238.89 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $92.274 million which beat the analyst consensus estimate of $67.861 million by 35.98 percent. This is a 31.26 percent increase over sales of $70.301 million the same period last year.

Earnings

Earnings Beats

CareDx Q2 2024 Adj. EPS $0.25 Beats $(0.14) Estimate, Sales $92.274M Beat $67.861M Estimate

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CareDx, presenting an average target of $16.67, a high estimate of $22.00, and a low estimate of $14.00. This current average reflects an increase of 26.29% from the previous average price target of $13.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1721232035_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of CareDx's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CareDx</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>CareDx's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining CareDx's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -6.75% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CareDx's net margin is impressive, surpassing industry averages. With a net margin of -23.12%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CareDx's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.44% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): CareDx's ROA excels beyond industry benchmarks, reaching -3.62%. This signifies efficient management of assets and strong financial health.
Debt Management: CareDx's debt-to-equity ratio surpasses industry norms, standing at 0.13. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where CareDx Stands With Analysts

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $14 to $16.

Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $16

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.5, a high estimate of $22.00, and a low estimate of $14.00. Observing a 26.92% increase, the current average has risen from the previous average price target of $13.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1717178476_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of CareDx by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CareDx's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering CareDx: A Closer Look</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>Understanding the Numbers: CareDx's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: CareDx's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -6.75%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CareDx's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -23.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CareDx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -6.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CareDx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.62% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: CareDx's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 6 Analyst Evaluations For CareDx

CareDx solutions are featured in 36 oral presentations and posters, and a symposium. The findings highlight innovative approaches, including AI integration, and the real-world clinical utility of CareDx&#39;s solutions, emphasizing their significant impact on patient care and outcomes in kidney, heart, and lung transplantation.

CareDx To Present New Data At The 2024 American Transplant Congress Being Held June 1-5 In Philadelphia

CareDx shares are trading lower. The company announced that it responded to Natera's filing of a motion for an injunction related to patent 11,111,544.

CareDx Reiterates Position that it Does Not Infringe Natera&#39;s &lsquo;544 Patent
Injunction Motion has No Impact on CareDx&#39;s Business or Patient and Clinician Access to AlloSure or AlloMap
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) &ndash; The Transplant Company&trade; focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers &ndash; today responded to Natera, Inc.&#39;s filing of a motion for an injunction related to patent 11,111,544 (the &lsquo;544 patent).
The motion seeks to stop CareDx from using a prior AlloSure&reg; process that Natera alleged infringed the &lsquo;544 patent. That process is no longer in effect. As CareDx informed Natera and the Court, since August 2023, CareDx has utilized a new AlloSure process that it believes does not infringe on the &lsquo;544 patent.
The underlying validity of the &lsquo;544 patent also remains subject to judicial review.
&quot;We believe the motion against a process that is no longer in effect is irrelevant, and the District Court is still considering the fundamental question of the validity of the &lsquo;544 patent,&quot; said John W. Hanna, CareDx President and CEO. &quot;We greatly appreciate the continued support of the transplant community as we seek to resolve these matters, allowing us to return our full attention to serving patients and developing clinical innovations that improve transplant care.&quot;
Natera has previously claimed infringement on three patents:
<ol>
<li>Prior to trial, the District Court dismissed patent 10,597,724 (the &lsquo;724 patent) as invalid as patent ineligible.</li>
<li>At trial, CareDx was found not to have infringed on patent 10,655,180 (the &lsquo;180 patent).</li>
<li>The &lsquo;544 patent is the subject of post-trial motion practice in which, among other things, CareDx is seeking to invalidate that patent on the same grounds as the &lsquo;724 patent.</li>
</ol>
Natera&#39;s motion does not impact CareDx&#39;s business or ability to continue providing transplant patients with AlloSure or AlloMap&reg;.

Biotech

Legal

General

NTRA

CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New AlloSure Process That It Believes Does Not Infringe On The '544 Patent.

H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx (CDNA – Research Report) today. The company's shares closed yesterday at $19.99....

H.C. Wainwright Keeps Their Hold Rating on CareDx (CDNA)

Baron Discovery Fund Q2 2024 Shareholder Letter

CareDx stock climbs 16% on Medicare coverage update

CareDx names Keith Kennedy as COO

CareDx ( ($CDNA) ) has shared an update. CareDx, Inc., a leading precision medicine solutions company in the transplant space, has announced the st...

CareDx Announces Key Executive Appointments and Investor Day

CareDx (CDNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mark Massaro from BTIG re...

Buy Rating Affirmed for CareDx: Leadership Enhancements and Undervalued Stock Present Growth Opportunities

Small-cap stocks have climbed recently. Here are the ones most poised for further upside

Wall Street Lunch: Intel Grabs Wall Street Attention

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

CareDx ( ($CDNA) ) has provided an update. CareDx, Inc. has concluded an employment separation and consulting agreement with Alexander Johnson, its...

CareDx Arranges Amicable Exit for Executive Alexander Johnson

ALAB

ALGM

AMZN

AQST

AVGO

AXNX

BASE

BCAP

BFLY

BROE

BYRN

CLOV

COMM

CRCQW

CURI

DAVE

DELL

ESOA

ESTA

EVER

EXAS

GTHX

GTLB

GWRE

HRTG

HYLN

INDI

INSG

INSP

INTC

ITGR

JAGGF

KNSL

MSFT

NVDA

NVMI

OPFI

PCOR

PRAX

PSIX

PSNL

RGEN

SILK

SITE

SMAR

SMCI

STVN

SUPV

TALK

TALKW

TSMWF

USAP

VCYT

Press Releases

CareDx Reiterates Position that it Does Not Infringe the '544 Patent, Injunction Motion is Irrelevant

AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress

Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients

CareDx to Report Second Quarter 2024 Financial Results

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)

CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance

CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing

CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

Comments

CareDx

뉴스

에 대한 최신 뉴스 CareDx (NASDAQ:CDNA) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌